The Life Sciences team advised BridgeBio Pharma, Inc. (Nasdaq: BBIO) on its underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million, excluding any exercise of the underwriters' option to purchase additional shares.

BridgeBio, headquartered in Palo Alto, CA, is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.

The Goodwin team was led by Maggie Wong, Natalie Martirossian, Jesse Fishman, Dan Liu, Sydney Shaffer, Alex Varond, Sarah Wicks, Roger Cohen, Heath Ingram, Dan Karelitz, Gregg Coughlin, Brad Weber and Ettore Santucci, with invaluable assistance from Jim Barri and Ruowen Li. 

For more details, read the press release and article in Endpoints News